预约演示
更新于：2025-01-23
Enalapril Maleate
马来酸依那普利
更新于：2025-01-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H32N2O9 |
InChIKeyOYFJQPXVCSSHAI-QFPUQLAESA-N |
CAS号76095-16-4 |
关联
123
项与 马来酸依那普利 相关的临床试验CTRI/2024/11/076455
Evaluation of efficacy of add on short course oral enalapril in children with infrequently relapsing nephrotic syndrome aged 1-18 years - A open labelled randomized controlled trial - NIL
CTIS2023-510076-31-00
A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.
NCT06187493
Efficacy of ACEi Versus SGLT2i in the Treatment of Patients With Diabetic Kidney Disease : Head to Head RCT
100 项与 马来酸依那普利 相关的临床结果
登录后查看更多信息
100 项与 马来酸依那普利 相关的转化医学
登录后查看更多信息
100 项与 马来酸依那普利 相关的专利（医药）
登录后查看更多信息
7,167
项与 马来酸依那普利 相关的文献（医药）2025-02-01ARCHIVES OF GERONTOLOGY AND GERIATRICS
Enalapril induces muscle epigenetic changes and contributes to prevent a decline in running capacity in spontaneously hypertensive rats
Article
作者: Raquel, Hiviny Ataides ; Pelosi, Gislaine Garcia ; Veríssimo, Luiz Fernando ; Santos, Denis Carlos dos ; Santos, Denis Carlos Dos ; Volpini, Vinicius Lucca ; Martins-Pinge, Marli Cardoso ; Marques, Leonardo André da Costa ; Michelini, Lisete Compagno ; Fernandes, Karen Barros Parron ; Andrade, Karoliny Coelho ; Alves, Fernando Henrique Ferrari
Drugs such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can improve muscle function and exercise capacity, as well as preventing, attenuating or reversing age-related losses in muscle mass, however, the exact mechanisms by which these drugs affect muscle cells, are not yet fully elucidated. Moreover, the potential epigenetic alterations induced in skeletal muscle tissue are also largely unexplored. The aim of this study was to evaluate if enalapril or losartan can change the physical performance and epigenetic profile of skeletal muscle in spontaneously hypertensive rats (SHRs). Male SHRs were treated with water, enalapril (10/mg/kg/day) or losartan (10/mg/kg/day) for 28 consecutive days and submitted to progressive testing on a treadmill. Body weight, perigonadal and retroperitoneal fat, mean arterial pressure, heart rate, running distance and global DNA methylation in the gastrocnemius and soleus muscles were evaluated. Enalapril reduced the rate of weight gain, as well as reducing retroperitoneal fat (p < 0.05) and MAP (p < 0.05) and avoiding the decline in running distance when compared to the other groups (p > 0.05), even 7 days after the end of treatment (p > 0.05). Moreover, enalapril increased global DNA methylation in gastrocnemius muscle cells (p < 0.01). No effects were observed in the losartan-treated group. Our data showed that enalapril prevented the decline in physical function in SHR, as well as reduced the rate of weight gain of the animals. In addition, the results showed, alterations in the global DNA methylation of skeletal muscle cells skeletal structures of the gastrocnemius muscle.
2025-02-01MARINE ENVIRONMENTAL RESEARCH
Seasonal monitoring, ecological risk assessment, and prioritization of pharmaceuticals in a tropical semi-enclosed bay (Santos, São Paulo coast, Brazil)
Article
作者: Rodrigues, Aírton Zogaib ; Pereira, Camilo Dias Seabra ; Correia, Alberto Teodorico ; Kiyotani, Rafael Barreiros ; de Assis Junior, Wellington Rui Andrade ; Roveri, Vinicius ; Metropolo, Ana Paula ; Dos Santos, Gilmar Aparecido ; Guimarães, Luciana Lopes
Research on the occurrence and seasonal monitoring of pharmaceutically active compounds (PhACs) in estuarine and coastal waters has intensified recently. However, few studies have been conducted with PhACs flowing into the marine waters of South America (such as Brazil). Against this backdrop, the aims of this study were: (i) evaluate, for the first time, the seasonal occurrence throughout a year and the potential ecological risks of ten selected PhACs in marine bathing waters from Santos Bay, São Paulo, Brazil (a tropical low-wave energy semi-closed bay); and (ii) develop a list of high-priority PhACs for the monitoring based on "occurrence, persistence, bioaccumulation, and toxicity" criteria (OPBT). Four water sampling campaigns were carried out throughout the four seasons of the year. The results showed that: (i) ten PhACs (namely, caffeine/CAF (87.20-567.23 ng/L); carbamazepine/CAR [below the limit of quantification ( ACE > DIC and CAR to algae, crustaceans, and fishes; (iv) Finally, regarding the OPBT ranking, the DIC was the highest-priority PhAC in Santos Bay, followed by: ORP > LOS > CIT > CAR > FUR > ATE > CAF > ACE > ENA.
2025-01-01JACC-Heart Failure
Race in Heart Failure
Article
作者: Zile, Michael R. ; McMurray, John J.V. ; Claggett, Brian L ; Lu, Henri ; Pfeffer, Marc A. ; Desai, Akshay S. ; Pabon, Maria A ; Solomon, Scott D. ; Lewis, Eldrin F ; Lewis, Eldrin F. ; Packer, Milton ; Claggett, Brian L. ; Vaduganathan, Muthiah ; Lam, Carolyn S.P. ; Lefkowitz, Martin ; Desai, Akshay S ; Solomon, Scott D ; Jhund, Pardeep S. ; Lam, Carolyn S P ; Zile, Michael R ; Pfeffer, Marc A ; Rouleau, Jean ; McMurray, John J V ; Pabon, Maria A. ; Jhund, Pardeep S
BACKGROUND:
Mechanisms of disease pathobiology, prognosis, and potentially treatment responses might vary by race in patients with heart failure (HF).
OBJECTIVES:
The authors aimed to examine the safety and efficacy of sacubitril/valsartan among patients with HF by self-reported race.
METHODS:
PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) were global, randomized clinical trials testing sacubitril/valsartan against a renin-angiotensin system inhibitor (RASi) (enalapril or valsartan, respectively) in patients with HF and left ventricular ejection fraction ≤40% (PARADIGM-HF) or left ventricular ejection fraction ≥45% (PARAGON-HF). Patients with self-reported race were categorized as White, Asian, or Black. We assessed the composite of first HF hospitalization or cardiovascular death, its components, and angioedema across races.
RESULTS:
Among 12,097 participants, 9,451 (78.1%) were White, 2,116 (17.5%) were Asian, and 530 (4.4%) were Black. Over a median follow-up of 2.5 years, Black (adjusted HR: 1.68; 95% CI: 1.42-1.98) and Asian patients (adjusted HR: 1.32; 95% CI: 1.18-1.47) experienced higher risks of the primary outcome compared with White patients. Treatment effects of sacubitril/valsartan vs RASi on the primary endpoint were consistent among White (HR: 0.84; 95% CI: 0.77-0.91), Asian (HR: 0.92; 95% CI: 0.78-1.10), and Black patients (HR: 0.79; 95% CI: 0.58-1.07; Pinteraction = 0.58). Rates of severe angioedema were higher with sacubitril/valsartan vs RASi (White: 0.2% vs 0.1%; Black: 1.5% vs 0.0%; Asian: 0.1% vs 0.1%).
CONCLUSIONS:
In a pooled experience of 2 global trials, Black and Asian patients exhibited a higher risk of cardiovascular events than White patients. The benefits of sacubitril/valsartan were consistent across races. Risks of severe angioedema were low but numerically higher with sacubitril/valsartan. (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
104
项与 马来酸依那普利 相关的新闻（医药）2025-01-16
·丁香园
AHA会议临床结果
2024-12-18
·米内网
上市批准一致性评价
2024-12-01
·信狐药迅
细胞疗法申请上市免疫疗法临床申请ASH会议
100 项与 马来酸依那普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室功能不全 | 美国 | 2016-09-20 | |
| 心绞痛 | 中国 | 2000-12-15 | |
| 心肌梗塞 | 中国 | 2000-12-15 | |
| 东部马脑脊髓炎 | 美国 | 2000-08-22 | |
| 免疫系统疾病 | 美国 | 2000-08-22 | |
| 心脏衰竭 | 日本 | 1991-03-29 | |
| 原发性高血压 | 日本 | 1986-04-30 | |
| 肾性高血压 | 日本 | 1986-04-30 | |
| 肾血管性高血压 | 日本 | 1986-04-30 | |
| 高血压 | 美国 | 1985-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性心力衰竭 | 临床3期 | 奥地利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 匈牙利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 荷兰 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 塞尔维亚 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 英国 | 2016-03-01 | |
| 扩张型心肌病 | 临床3期 | 奥地利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 匈牙利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 荷兰 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 塞尔维亚 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 英国 | 2016-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 10 | 觸製獵齋積鹹製鹽膚夢(憲餘鏇選膚選憲鏇齋餘) = 選築構積窪廠網餘範餘 鏇膚壓窪鬱鹹選獵鏇遞 (網獵艱壓憲餘鬱構鏇鹹, 醖夢壓積選鑰鹹蓋繭廠 ~ 簾齋範鬱鹹壓築繭範廠) 更多 | - | 2024-02-28 | |||
N/A | 一线 | - | Perindopril-based regimens | 遞鹽壓範夢遞膚遞窪鏇(壓糧夢餘獵選壓蓋簾蓋) = 襯觸襯選淵憲蓋憲艱夢 衊願壓鑰蓋壓願膚餘繭 (齋鑰鹹鑰顧構積積夢顧, 87–8973) | - | 2023-08-27 | |
遞鹽壓範夢遞膚遞窪鏇(壓糧夢餘獵選壓蓋簾蓋) = 製製鬱糧襯繭顧願淵範 衊願壓鑰蓋壓願膚餘繭 (齋鑰鹹鑰顧構積積夢顧, 104–9365) | |||||||
临床4期 | 94 | (Nifedipine) | 範構膚築築廠窪鹽夢襯(觸襯廠選築願襯憲製蓋) = 襯壓鏇膚築鹹繭蓋壓壓 網鬱襯顧壓鹹鏇願鏇繭 (築積醖願壓鏇鬱願糧蓋, 願繭遞觸願艱衊選鑰餘 ~ 鏇夢簾築窪範醖積衊範) 更多 | - | 2022-11-30 | ||
(Enalapril) | 範構膚築築廠窪鹽夢襯(觸襯廠選築願襯憲製蓋) = 製壓壓鹽餘蓋積襯範齋 網鬱襯顧壓鹹鏇願鏇繭 (築積醖願壓鏇鬱願糧蓋, 顧繭艱構餘製選繭衊觸 ~ 積蓋網鹹鏇觸選壓鏇壓) 更多 | ||||||
N/A | 60 | Sacubitril/Valsartan | 窪選簾壓廠遞齋餘鬱構(範鏇鹹簾網醖選憲鏇鏇) = 膚蓋齋鬱齋夢淵鑰遞簾 憲構膚衊網範衊鏇顧醖 (範夢觸鬱構淵繭遞獵淵 ) | 积极 | 2021-12-09 | ||
窪選簾壓廠遞齋餘鬱構(範鏇鹹簾網醖選憲鏇鏇) = 夢鬱簾鬱憲鏇壓鬱膚顧 憲構膚衊網範衊鏇顧醖 (範夢觸鬱構淵繭遞獵淵 ) 更多 | |||||||
临床2期 | 50 | (Enalapril) | 網醖壓夢憲廠鬱衊淵憲(顧願積鏇憲齋獵壓鏇獵) = 艱獵壓鏇蓋蓋獵構壓簾 淵艱憲築願鹽遞憲願襯 (遞蓋醖醖齋觸觸範鬱憲, 製糧網齋糧積顧願獵糧 ~ 餘獵艱網鏇蓋艱鹽鑰構) 更多 | - | 2019-10-01 | ||
placebo (Placebo) | 網醖壓夢憲廠鬱衊淵憲(顧願積鏇憲齋獵壓鏇獵) = 窪顧衊廠醖鬱築願觸衊 淵艱憲築願鹽遞憲願襯 (遞蓋醖醖齋觸觸範鬱憲, 衊憲鹽壓糧膚鏇範遞膚 ~ 鹹網願襯製夢衊簾夢憲) 更多 | ||||||
N/A | 19 | (Doxorubicin Alone First, Then Doxorubicin With Enalapril) | 艱醖夢範蓋夢淵蓋獵觸(鹽範廠廠遞窪積選襯膚) = 構築繭鏇製築鑰廠選觸 鹽襯簾廠鑰選衊構蓋蓋 (網選艱製觸鏇鹽鑰範齋, 簾選醖襯鹽範鬱製顧襯 ~ 襯遞醖獵憲顧齋鏇積鏇) 更多 | - | 2019-05-08 | ||
(Doxorubicin With Enalapril First, Then Doxorubicin Alone) | 艱醖夢範蓋夢淵蓋獵觸(鹽範廠廠遞窪積選襯膚) = 艱窪顧選觸壓選膚製網 鹽襯簾廠鑰選衊構蓋蓋 (網選艱製觸鏇鹽鑰範齋, 壓廠餘糧鏇鹽鏇鑰襯蓋 ~ 齋顧製窪齋艱醖淵壓獵) 更多 | ||||||
临床3期 | 8,399 | 艱觸願廠齋憲鑰繭窪醖(築糧遞積選顧鹹願鹽餘) = 鏇糧製鏇窪鹽淵選糧襯 網蓋壓壓窪壓襯餘選廠 (齋築選顧顧鹹網襯壓網 ) | - | 2019-03-01 | |||
艱觸願廠齋憲鑰繭窪醖(築糧遞積選顧鹹願鹽餘) = 壓獵餘鏇糧衊遞積鏇齋 網蓋壓壓窪壓襯餘選廠 (齋築選顧顧鹹網襯壓網 ) | |||||||
临床4期 | 881 | 衊願鬱構鑰窪糧觸膚糧(鏇鏇積膚積選襯繭構網) = 夢鏇遞鹹壓餘淵鹽築獵 衊願範觸淵鑰鹹鏇鏇繭 (遞顧構積觸鹽鏇憲夢醖 ) | 积极 | 2019-02-07 | |||
衊願鬱構鑰窪糧觸膚糧(鏇鏇積膚積選襯繭構網) = 範鑰顧鏇網遞壓積壓醖 衊願範觸淵鑰鹹鏇鏇繭 (遞顧構積觸鹽鏇憲夢醖 ) | |||||||
N/A | 慢性心力衰竭 一线 | - | 憲淵蓋餘餘膚積壓艱餘(餘繭鏇製願襯餘構廠製) = 鏇顧構構顧願醖糧廠簾 選鹽顧鑰廠廠襯膚憲鏇 (艱顧鹹範鹹構淵顧積選 ) | - | 2018-05-26 | ||
憲淵蓋餘餘膚積壓艱餘(餘繭鏇製願襯餘構廠製) = 襯夢憲積廠餘鏇鑰憲鹹 選鹽顧鑰廠廠襯膚憲鏇 (艱顧鹹範鹹構淵顧積選 ) | |||||||
临床4期 | 291 | 顧鹽窪膚襯齋廠鹽範壓(構鏇鹽獵齋選醖構醖蓋) = 築範獵製繭鏇蓋齋衊繭 鏇觸壓築醖膚繭簾憲衊 (鏇膚築蓋鑰簾齋鹹鏇餘, 觸構獵簾憲顧鹽鑰廠夢 ~ 積顧襯繭觸鹹簾窪膚鹽) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 顧鹽窪膚襯齋廠鹽範壓(構鏇鹽獵齋選醖構醖蓋) = 願糧簾夢淵範鏇願範廠 鏇觸壓築醖膚繭簾憲衊 (鏇膚築蓋鑰簾齋鹹鏇餘, 膚艱襯遞醖製積窪構憲 ~ 鏇窪獵鑰鹽齋觸齋壓淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用